Cell Biology Program
The Alban Ordureau Lab
My group focuses on understanding cell signaling pathways primarily linked with the ubiquitin and autophagy systems and frequently altered in diseases, including neurodegenerative disease. To this end, we combine cell biological, genome engineering (CRISPR), and biochemical approaches to provide new insights into mechanisms regulating various aspects of cellular homeostasis. Central to our research efforts, we employ and develop multiple quantitative proteomics workflows to examine how flux in signaling systems (e.g., phosphorylation, ubiquitylation, protein translation, degradation, and trafficking) is altered in response to perturbations or disease mutations.
Ordureau, A., Paulo, J.A., Zhang, J., An, H., Swatek, K.N., Cannon, J.R., Wan, Q., Komander, D. & Harper, J.W. (2020) Global landscape and dynamics of Parkin and USP30-dependent ubiquitylomes in iNeurons during mitophagic signaling. Molecular Cell 77(5):1124-1142.e10.
An, H.*, Ordureau, A.*, Korner, M., Paulo, J.A. & Harper, J.W. (2020) Systematic quantitative analysis of ribosome inventory during nutrient stress. Nature 583(7815):303-309. (* equal contribution)
Ordureau, A., Sarraf, S.A., Duda, D.M., Heo, J.M., Jedrychowski, M.P., Sviderskiy, V.O., Olszewski, J.L., Koerber, J.T., Xie, T., Beausoleil, S.A., Wells, J.A., Gygi, S.P., Schulman, B.A. & Harper, J.W. (2014) Quantitative proteomics reveal a feedforward mechanism for mitochondrial Parkin translocation and ubiquitin chain synthesis. Molecular Cell 56, 360-75.
Alban Ordureau, PhD
- Alban Ordureau explores molecular signaling pathways that regulate cellular homeostasis, with a focus on the ubiquitin and autophagy systems.
- PhD, MRC-PPU - University of Dundee, Scotland, UK
- Post-doctoral training - Harvard Medical School, Boston
- Edward R. and Anne G. Lefler Center Fellow
Applications are invited for Postdoctoral Researchers to work in the laboratory of Alban Ordureau in the Cell Biology Department at Memorial Sloan Kettering Cancer Center (MSK) in New York.
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Alban Ordureau discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.